Room 3 — Controller Room 3

진행 중: —
--:--

세션 목록 (10개)

15:20~16:401
Continuous glucose monitoring, diabetes in pregnancy Clinical application of continuous glucose monitoring in diabetes in pregnancy
예정
1
김원진 차의과학대 내과 15:20-15:40
Clinical evidence for continuous glucose monitoring during pregnancy
2
김지민 한국보건의료연구원 15:40-16:00
Continuous glucose monitoring in gestational diabetes mellitus: a systematic review and meta-analysis
3
송나현 서울의대 내과 16:00-16:20
Integration of continuous glucose monitoring in the Korean gestational diabetes mellitus (KGDM) prospective cohort
16:50~17:501
β-cell function and maturation Molecular and cellular mechanisms regulating pancreatic β-cell function and maturation
예정
1
전예슬 한국화학연구원 의약바이오본부 16:50-17:05
Engineered vasculature induces functional maturation of pluripotent stem cell-derived islet organoids
2
김용경 영남대 의과학연구소 17:05-17:20
Loss of LDHA in β-cells enhances mitochondrial respiration and glucose tolerance through metabolic change
3
이재민 DGIST 17:20-17:35
Endoplasmic reticulum stress and its associated signaling trigger incretin resistance in pancreatic β cells during type 2 diabetes
4
이은경 가톨릭의대 생화학교실 17:35-17:50
Intracellular zinc signaling via Krüppel-like transcription factor 6 promotes HuD expression in pancreatic β cells
09:00~10:202
Therapeutic strategies of SGLT-2 inhibitors Clinical evidence-based selection and therapeutic expansion strategies for SGLT-2 inhibitors
예정
1
강신애 연세의대 내과 09:00-09:25
Optimizing SGLT2 inhibitor therapy through shared mechanisms and distinct clinical differences
2
민세희 울산의대 내과 09:25-09:50
Positioning enavogliflozin within the evolving landscape of SGLT2 inhibitors
3
김신곤 고려의대 내과 09:50-10:15
How Korean SGLT-2i compares with global standards in cardiorenal protection: insights from the ENVELOP study
12:20~12:352
Luncheon symposium 3 Detect early act early: improving outcome in CKD with T2D
예정
1
김규리 성균관의대 내과 12:20-12:35
Detect early act early: improving outcome in CKD with T2D
12:35~12:502
Luncheon symposium 6 Synergistic metabolic control: the power of TZD and SGLT2 inhibitor combination
예정
1
정인하 고려의대 내과 12:35-12:50
Synergistic metabolic control: the power of TZD and SGLT2 inhibitor combination
14:00~15:202
nsMRA in integrated CKM care Practical use of finerenone and future evidence
예정
1
류혜진 고려의대 내과 14:00-14:25
Finerenone in CKD with T2D: early intervention and CONFIDENCE insights
2
김다래 성균관의대 내과 14:25-14:50
The role of finerenone in heart failure management: outcomes and clinical implication
3
곽수헌 서울의대 내과 14:50-15:15
From FINE-ONE results to next-generation trials: the research roadmap for finerenone
09:00~10:203
Optimizing GLP 1 therapy for diabetes Targeting diabetes comorbidities: why semaglutide?
예정
1
허규연 성균관의대 내과 09:00-09:25
Key trial results in semaglutide: clinical evidence transforming diabetes and comorbidity management
2
김남훈 고려의대 내과 09:25-09:50
Renoprotective effects of semaglutide: mechanisms and clinical evidence
3
이은영 가톨릭의대 내과 09:50-10:15
Semaglutide for cardioprotection: advancing outcomes in high‑risk diabetes patients
12:20~12:353
Luncheon symposium 10 Does switching within the DPP 4 inhibitor class make a real difference?: integrating Korean RWE into diabetes care
예정
1
김진화 조선의대 내과 12:20-12:35
Does switching within the DPP 4 inhibitor class make a real difference?: integrating Korean RWE into diabetes care
12:35~12:503
Luncheon symposium 14 Beyond the statin; start early, switch now
예정
1
홍상모 한양의대 내과 12:35-12:50
Beyond the statin; start early, switch now
14:00~15:203
The paradigm shift in diabetes care driven by CGM How continuous glucose monitoring is redefining clinical approaches, treatment strategies, and patient outcomes in diabetes care
예정
1
정진우 원광의대 내과 14:00-14:25
CGM era: evidence, gaps, and the path forward
2
진상만 성균관의대 내과 14:25-14:50
Clinical decision-making with CGM data: interpretation, pattern analysis, and therapeutic optimization
3
문선준 성균관의대 내과 14:50-15:15
Future directions of CGM technology: from inpatient application to AI-driven integrated diabetes management